Shin Nippon Biomedical Laboratories 2395.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 2395.T. It has been listed since 8 March 2004. In the fiscal year to 31 March 2026, it reported revenue of ¥32.52bn and net income of ¥4.57bn. At that date it held total assets of ¥105.06bn and shareholders' equity of ¥43.12bn.

Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. The company is headquartered in Chuo-Ku, Tokyo-To. The company went IPO on 2004-03-08. The firm has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Ryoichi NagataChairman of the Board, President, Chief Executive Officer, Chief Health Officer, Representative Director, since 1991
• Mr. Naohiro TsuharaExecutive Officer, Senior Director of Finance and Accounting
• Mr. Ichiro NagataVice President, Director, since 2018
• Mr. Ken TakanashiVice President, Representative Director, since 2004
• Mr. Hideshi TsusakiSenior Managing Director
• Ms. Kiyomi NagatoshiSenior Managing Executive Officer, Chief Director of General Affairs and Human Resources, since 2024
• Mr. Takashi IriyamaSenior Managing Executive Officer, Chief Director of Business Strategy
• Mr. Shinji NitandaSenior Managing Executive Officer, since 2023
• Mr. Toshiyuki IwataManaging Executive Officer, Senior Director of IR & Public Relations, since 2022
• Mr. Terumasa HiraiManaging Executive Officer, Vice President of Non-Clinical Company, President of Subsidiary, since 2024
• Mr. Shuichi KanazashiManaging Executive Officer, Chief Medical Officer, President of TR Company, Chief Director of TR Business in TR Company
• Mr. Satoshi MatsumotoManaging Executive Officer, Director of Fisheries Business, since 2012

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.